Relmada Therapeutics (STU:4E2) Cyclically Adjusted Book per Share: €2.89 (As of Mar. 2026)


STU:4E2 Relmada Therapeutics Inc STU:4E2
22 GF Score
Price €5.65
! 2 Warning Signs
View Full Analysis

What is Relmada Therapeutics Cyclically Adjusted Book per Share?

Relmada Therapeutics STU:4E2 22 Cyclically Adjusted Book per Share is €2.89 as of Mar. 2026. GuruFocus rates STU:4E2 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Relmada Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €1.804. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.89 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Relmada Therapeutics's average Cyclically Adjusted Book Growth Rate was -8.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Relmada Therapeutics was 20.10% per year. The lowest was 8.10% per year. And the median was 14.10% per year.

As of today (2026-07-11), Relmada Therapeutics's current stock price is €5.65. Relmada Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €2.89. Relmada Therapeutics's Cyclically Adjusted PB Ratio of today is 1.96.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Relmada Therapeutics was 1.91. The lowest was 0.00. And the median was 0.00.


Relmada Therapeutics  (STU:4E2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Relmada Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.65/2.89
=1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Relmada Therapeutics was 1.91. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Relmada Therapeutics Cyclically Adjusted Book per Share Related Terms


Relmada Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Relmada Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics Cyclically Adjusted Book per Share Chart

Relmada Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.79 2.54 2.57 2.61 2.63

Relmada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.40 3.08 2.73 2.63 2.89

STU:4E2 vs ACRS, GYRE, SGP: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Relmada Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:4E2
22GF Score
Relmada Therapeutics Inc STU:4E2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relmada Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Relmada Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.804/330.2130*330.2130
=1.804

Current CPI (Mar. 2026) = 330.2130.

Relmada Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.083 241.018 2.854
201609 1.650 241.428 2.257
201612 1.473 241.432 2.015
201703 0.870 243.801 1.178
201706 0.415 244.955 0.559
201709 0.392 246.819 0.524
201712 0.194 246.524 0.260
201803 -0.599 249.554 -0.793
201806 -1.504 251.989 -1.971
201809 -2.388 252.439 -3.124
201812 0.169 251.233 0.222
201903 0.054 254.202 0.070
201906 0.691 256.143 0.891
201909 0.546 256.759 0.702
201912 7.201 256.974 9.253
202003 6.854 258.115 8.768
202006 7.407 257.797 9.488
202009 6.409 260.280 8.131
202012 5.314 260.474 6.737
202103 4.571 264.877 5.699
202106 4.602 271.696 5.593
202109 3.530 274.310 4.249
202112 6.644 278.802 7.869
202203 6.497 287.504 7.462
202206 6.202 296.311 6.912
202209 5.866 296.808 6.526
202212 4.405 296.797 4.901
202303 3.893 301.836 4.259
202306 3.414 305.109 3.695
202309 3.136 307.789 3.364
202312 2.600 306.746 2.799
202403 2.197 312.332 2.323
202406 1.893 314.175 1.990
202409 1.422 315.301 1.489
202412 1.124 315.605 1.176
202503 0.625 319.799 0.645
202506 0.417 322.561 0.427
202509 0.243 324.800 0.247
202512 1.007 324.054 1.026
202603 1.804 330.213 1.804

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €2.89 mean?
Relmada Therapeutics (STU:4E2) has a Cyclically Adjusted Book per Share of €2.89 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Relmada Therapeutics and its competitors.
Is Relmada Therapeutics' Cyclically Adjusted Book per Share too high?
Relmada Therapeutics' current Cyclically Adjusted Book per Share is €2.89. Overall, Relmada Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' Cyclically Adjusted Book per Share compare to ACRS and GYRE?
Relmada Therapeutics' Cyclically Adjusted Book per Share of €2.89 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Relmada Therapeutics and its competitors. Relmada Therapeutics's current Cyclically Adjusted Book per Share is €2.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (STU:4E2) has a current Cyclically Adjusted Book per Share of €2.89. The current Cyclically Adjusted Book per Share is €2.89. Relmada Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Relmada Therapeutics (STU:4E2), the current Cyclically Adjusted Book per Share is €2.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relmada Therapeutics Business Description

Other Exchanges RLMD:USA
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
22GF Score

Get the complete analysis for STU:4E2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.65
Price